1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): Action in other targets and antitargets

Current Medicinal Chemistry

Volumn 19, Issue 25, 2012, Pages 4306-4323

  Carosati, E ^a   Ioan, P ^b   Micucci, M ^b   Broccatelli, F ^a   Cruciani, G ^a   Zhorov, B S ^c,d   Chiarini, A ^b   Budriesi, R ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

1,4 Dihydropyridine; Alzheimer disease; Anti atherosclerotic action; Antitargets; Calcium antagonists; Cytochromes P450; Glucorticoid hormone receptors; HIV 1 protease inhibitors; MDR; Oxidative stress prevention; P gp; PAF antagonists; TRH; Tuberculosis

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 2,4,6 TRIMETHYL 1,4 DIHYDRO 3,5 PYRIDINEDICARBOXYLIC ACID 2 (3,4 DICHLOROPHENOXY)ETHYL BIS(MORPHOLINOMETHYL)METHYL ESTER; AMIODARONE; ANTINEOPLASTIC AGENT; APAFANT; CALCIUM CHANNEL BLOCKING AGENT; CEREBROCRAST; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DEXNIGULDIPINE; G PROTEIN COUPLED RECEPTOR; GINKGOLIDE B; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; ION CHANNEL; J 6163; LAU 0900; MEMBRANE PROTEIN; MINERALOCORTICOID RECEPTOR; MODIPAFANT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NICARDIPINE; NIFEDIPINE; NIK 250; NILUDIPINE; NIMODIPINE; OSI 1211; OSI 1580; OSI 2140; OSI 2780; OSI 4164; OSI 7265; OSI 7724; POTASSIUM CHANNEL HERG; RIODIPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE; XENOBIOTIC AGENT;

AEROBIC METABOLISM; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CELL; CELL STRUCTURE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYDROPHOBICITY; IC 50; IN VITRO STUDY; MEDIATOR; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PHARMACOPHORE; PHYTOCHEMISTRY; PROTEIN EXPRESSION; REVIEW; RING OPENING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUBERCULOSIS;

ALZHEIMER DISEASE; ANIMALS; ANTITUBERCULAR AGENTS; ATHEROSCLEROSIS; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROPYRIDINES; DRUG RESISTANCE, MULTIPLE; HUMANS; PLATELET ACTIVATING FACTOR; TUBERCULOSIS;

EID: 84866687385     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802884204     Document Type: Review

References (167)

1. Ioan, P.; Carosati, E.; Micucci, M.; Broccatelli, F.; Cruciani, G.; Zhorov, B.S.; Chiarini, A.; Budriesi, R. 1, 4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives. (Part 1): Action in Ion Channels and GPCRs. Curr. Med. Chem., 2011, 18, 4901-4922.
2. Vaz, R.J.; Klabunde, T. In: Antitargets: Prediction and Prevention of Drug Side Effects Wiley-VCH, Weinheim: 2008, pp XXI-XXIV.
3. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta., 1976, 455, 152-162.
4. Mehdipour, A.R.; Javidnia, K.; Hemmateenejad, B.; Amirghofran, Z.; Miri, R. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem. Biol. Drug Des., 2007, 70, 337-346.
5. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Increased Accumulation of Vincristine and Adriamycin in Drug-resistant P388 Tumor Cells following Incubation with Calcium Antagonists and Calmodulin Inhibitors. Cancer Res., 1982, 42, 4730-4733.
6. Tsuruo, T.; Iida, H.; Nojiri, M.; Tsukagoshi, S.; Sakurai, Y. Circumvention of Vincristine and Adriamycin Resistance in Vitro and in Vivo by Calcium Influx Blockers. Cancer Res., 1983, 43, 2905-2910.
7. Ichiro, N.; Kimitoshi, K.; Junko, K.; Michihiko, K.; Shin-Ichi, A.; Akira, K.; Ken-Ichi, S.; Yohji, Y.; Cornwell, M.M.; Pastan, I.; Gottesman, M.M. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol., 1989, 38, 519-527.
8. Philip, P.A.; Joel, S.; Monkman, S.C.; Dolega-Ossowski, E.; Tonkin, K.; Carmichael, J.; Idle, J.R.; Harris, A.L. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br. J. Cancer, 1992, 65, 267-270.
9. Hofmann, J.; Ueberall, F.; Egle, A.; Grunicke, H. B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. Int. J. Cancer, 1991, 47, 870-874.
10. Hofmann, J.; Wolf, A.; Spitaler, M.; Bock, G.; Drach, J.; Ludescher, C.; Grunicke, H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol., 1992, 118, 361-366.
11. Hofmann, J.; Gekeler, V.; Ise, W.; Noller, A.; Mitterdorfer, J.; Hofer, S.; Utz, I.; Gotwald, M.; Boer, R.; Glossmann, H.; Grunicke, H.H. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol., 1995, 49, 603-609.
12. Ukena, D.; Boewer, C.; Oldenkott, B.; Rathgeb, F.; Wurst, W.; Zech, K.; Sybrecht, G.W. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I doseescalation trial. Cancer Chemother. Pharmacol., 1995, 36, 160-164.
13. Tanabe, H.; Tasaka, S.; Ohmori, H.; Gomi, N.; Sasaki, Y.; Machida, T.; Iino, M.; Kiue, A.; Naito, S.; Kuwano, M. Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance. Bioorgan. Med. Chem., 1998, 6, 2219-2227.
14. Tasaka, S.; Ohmori, H.; Gomi, N.; Iino, M.; Machida, T.; Kiue, A.; Naito, S.; Kuwano, M. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg. Med. Chem. Lett., 2001, 11, 275-277.
15. Capolongo, L.; Amboldi, N.; Ballinari, D.; Cozzi, P.; Melegaro, G.; Ripamonti, M.; Vaghi, F.; Grandi, M. Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity. Acta Oncol., 1994, 33, 787-791.
16. Kawase, M.; Shah, A.; Gaveriya, H.; Motohashi, N.; Sakagami, H.; Varga, A.; Molnar, J. 3, 5-dibenzoyl-1, 4-dihydropyridines: synthesis and MDR reversal in tumor cells. Bioorgan. Med. Chem., 2002, 10, 1051-1055.
17. D'Elia, P.; De Matteis, F.; Dragoni, S.; Shah, A.; Sgaragli, G.; Valoti, M. DP7, a novel dihydropyridine multidrug resistance reverter, shows only weak inhibitory activity on human CYP3A enzyme(s). Eur. J. Pharmacol., 2009, 614, 7-13.
18. Saponara, S.; Kawase, M.; Shah, A.; Motohashi, N.; Molnar, J.; Ugocsai, K.; Sgaragli, G.; Fusi, F., 3, 5-Dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2, 6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. Brit. J. Pharmacol., 2004, 141, 415-422.
19. Saponara, S.; Ferrara, A.; Gorelli, B.; Shah, A.; Kawase, M.; Motohashi, N.; Molnar, J.; Sgaragli, G.; Fusi, F., 3, 5-dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2, 6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart. Eur. J. Pharmacol., 2007, 563, 160-163.
20. Fusi, F.; Saponara, S.; Valoti, M.; Dragoni, S.; D'Elia, P.; Sgaragli, T.; Alderighi, D.; Kawase, M.; Shah, A.; Motohashi, N.; Sgaragli, G. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets, 2006, 7, 949-959.
21. Budriesi, R.; Ioan, P.; Locatelli, A.; Cosconati, S.; Leoni, A.; Ugenti, M.P.; Andreani, A.; Di Toro, R.; Bedini, A.; Spampinato, S.; Marinelli, L.; Novellino, E.; Chiarini, A. Imidazo[2, 1-b]thiazole System: A Scaffold Endowing Dihydropyridines with Selective Cardiodepressant Activity. J. Med. Chem., 2008, 51, 1592-1600.
22. Viale, M.; Cordazzo, C.; de Totero, D.; Budriesi, R.; Rosano, C.; Leoni, A.; Ioan, P.; Aiello, C.; Croce, M.; Andreani, A.; Rambaldi, M.; Russo, P.; Chiarini, A.; Spinelli, D. Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Invest. New Drugs, 2011, 29, 98-109.
23. Zhou, X.F.; Coburn, R.A.; Morris, M.E. Effects of new 4-aryl-1, 4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J. Pharm. Sci.-Us., 2005, 94, 2256-2265.
24. Zhou, X.F.; Zhang, L.; Tseng, E.; Scott-Ramsay, E.; Schentag, J.J.; Coburn, R.A.; Morris, M.E. New 4-aryl-1, 4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab. Dispos., 2005, 33, 321-328.
25. Zhou, X.F.; Yang, X.; Wang, Q.; Coburn, R.A.; Morris, M.E. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab. Dispos., 2005, 33, 1220-1228.
26. Voigt, B.; Coburger, C.; Monar, J.; Hilgeroth, A. Structure-activity relationships of novel N-acyloxy-1, 4-dihydropyridines as P-glycoprotein inhibitors. Bioorgan. Med. Chem., 2007, 15, 5110-5113.
27. Miri, R.; Mehdipour, A. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR. Bioorgan. Med. Chem., 2008, 16, 8329-8334.
28. Coburger, C.; Lage, H.; Molnar, J.; Hilgeroth, A. Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. Pharm. Res., 2009, 26, 182-188.
29. Coburger, C.; Wollmann, J.; Krug, M.; Baumert, C.; Seifert, M.; Molnar, J.; Lage, H.; Hilgeroth, A. Novel structure-activity relationships and selectivity profiling of cage dimeric 1, 4-dihydropyridines as multidrug resistance (MDR) modulators. Bioorgan. Med. Chem., 2010, 18, 4983-4990.
30. Richter, M.; Molnar, J.; Hilgeroth, A. Biological evaluation of bishydroxymethyl-substituted cage dimeric 1, 4-dihydropyridines as a novel class of P-glycoprotein modulating agents in cancer cells. J. Med. Chem., 2006, 49, 2838-2840.
31. Wollmann, J.; Richter, M.; Molnar, J.; Hilgeroth, A. First insight into the symmetry and flexibility of membrane efflux pump P-glycoprotein by novel bifunctional modulators. Chem. Bio. Chem., 2005, 6, 1353-1356.
32. Wollmann, J.; Molnar, J.; Hilgeroth, A. Physicochemical characteristics of novel P-glycoprotein inhibitors of the cage dimeric 1, 4-dihydropyridine type. Med. Chem., 2006, 2, 565-568.
33. Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, F.P.; Wilkinson, G.R.; Wood, A.J.J. P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies. Cancer Res., 1999, 59, 3944-3948.
34. Heitzer, M.D.; Wolf, I.M.; Sanchez, E.R.; Witchel, S.F.; DeFranco, D.B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord., 2007, 8, 321-330.
35. Akiyama, H.; Arai, T.; Kondo, H.; Tanno, E.; Haga, C.; Ikeda, K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord., 2000, 14 Suppl 1, S47-S53.
36. Yanamadala, V.; Friedlander, R.M. Complement in neuroprotection and neurodegeneration. Trends Mol. Med., 2010, 16, 69-76.
37. Sugaya, K.; Uz, T.; Kumar, V.; Manev, H. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn. J. Pharmacol., 2000, 82, 85-94.
38. Vaitkuviene, A.; Ulinskaite, A.; Meskys, R.; Duburs, G.; Klusa, V.; Liutkevicius, E. Study of the interaction of 1, 4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol. Rep. PR, 2006, 58, 551-558.
39. Shen, T.Y.; Hwang, S.B.; Chang, M.N.; Doebber, T.W.; Lam, M.H.; Wu, M.S.; Wang, X. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor. Int. J. Tissue React., 1985, 7, 339-343.
40. Shen, T.Y.; Hwang, S.B.; Chang, M.N.; Doebber, T.W.; Lam, M.H.; Wu, M.S.; Wang, X.; Han, G.Q.; Li, R.Z. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. P. Natl. Acad. Sci. USA, 1985, 82, 672-676.
41. Braquet, P., Bn 52021 and Related-Compounds -a New Series of Highly Specific Paf-Acether Receptor Antagonists. Prostaglandins, 1985, 30, 687-687.
42. Fujita, M.; Seki, T. Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). Bioorg. Med. Chem. Lett., 2002, 12, 1383-1386.
43. Handley, D.A.; Van Valen, R.G.; Melden, M.K.; Houlihan, W.J.; Saunders, R.N. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. J. Pharmacol. Exp. Ther., 1988, 247, 617-623.
44. Alker, D.; Campbell, S.F.; Cross, P.E.; Burges, R.A.; Carter, A.J.; Gardiner, D.G. Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N- substitutedheterocyclyl) ethoxy]methyl]-1, 4-dihydropyridine calcium antagonists. J. Med. Chem., 1990, 33, 1805-1811.
45. Cooper, K.; Fray, M.J.; Parry, M.J.; Richardson, K.; Steele, J. 1, 4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives. J. Med. Chem., 1992, 35, 3115-3129.
46. Kuitert, L.M.; Angus, R.M.; Barnes, N.C.; Barnes, P.J.; Bone, M.F.; Chung, K.F.; Fairfax, A.J.; Higenbotham, T.W.; O'Connor, B.J.; Piotrowska, B. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am. J. Respir. Crit. Care Med., 1995, 151, 1331-1335.
47. Sunkel, C.E.; Fau de Casa-Juana, M.; Cillero, F.J.; Priego, J.G.; Ortega, M.P. Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1, 4-dihydropyridines. J. Med. Chem., 1988, 31, 1886-1890.
48. Ortega, M.P.; Garcia, M.C.; Gijon, M.A.; de Casa-Juana, M.F.; Priego, J.G.; Sanchez Crespo, M.; Sunkel, C. 1, 4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. J. Pharmacol. Exp. Ther., 1990, 255, 28-33.
49. Fernandez-Gallardo, S.; Ortega, M.P.; Priego, J.G.; de Casa-Juana, M.F.; Sunkel, C.; Sanchez Crespo, M. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies. J. Pharmacol. Exp. Ther., 1990, 255, 34-39.
50. Bazan, N.G.; Sunkel, C.; Marcheselli, V.L.; Buillia, G.J. 2, 4, 6-trimethyl-1, 4-dihydro-pyridine-3, 5-dicarboxylic acid esters as neuroprotective drugs. US 6, 566, 359 B1, May, 20, 2003.
51. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003, 2, 539-547.
52. Boller, F.; Forette, F. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. Biomed. Pharmacother. 1989, 43, 487-491.
53. Lahiri, D.K.; Rogers, J.T.; Greig, N.H.; Sambamurti, K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr. Pharm. Des., 2004, 10, 3111-3119.
54. Supnet, C.; Bezprozvanny, I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J. Alzheimers Dis., 2010, 20 Suppl 2, S487-S498.
55. Kuchibhotla, K.V.; Goldman, S.T.; Lattarulo, C.R.; Wu, H.Y.; Hyman, B.T.; Bacskai, B.J. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron, 2008, 59, 214-225.
56. Rook, Y.; Schmidtke, K.U.; Gaube, F.; Schepmann, D.; Wunsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent -carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem., 2010, 53, 3611-3617.
57. Marco-Contelles, J.; Leon, R.; de Los Rios, C.; Guglietta, A.; Terencio, J.; Lopez, M.G.; Garcia, A.G.; Villarroya, M. Novel multipotent tacrinedihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 2006, 49, 7607-7610.
58. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F.J.; Rodriguez-Franco, M.I.; Lopez, B.; Lopez, M.G.; Garcia, A.G.; Carreiras Mdo, C.; Villarroya, M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitargetdirected ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52, 2724-2732.
59. Kapkova, P.; Stiefl, N.; Surig, U.; Engels, B.; Baumann, K.; Holzgrabe, U. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type. Arch. Pharm. (Weinheim), 2003, 336, 523-540.
60. Kapkova, P.; Alptuzun, V.; Frey, P.; Erciyas, E.; Holzgrabe, U. Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. Bioorg. Med. Chem., 2006, 14, 472-478.
61. Alptuzun, V.; Prinz, M.; Horr, V.; Scheiber, J.; Radacki, K.; Fallarero, A.; Vuorela, P.; Engels, B.; Braunschweig, H.; Erciyas, E.; Holzgrabe, U. Interaction of (benzylidene-hydrazono)-1, 4-dihydropyridines with betaamyloid, acetylcholine, and butyrylcholine esterases. Bioorg. Med. Chem., 2010, 18, 2049-2059.
62. Bodor, N.; Farag, H.H.; Brewster, M.E. Site-specific, sustained release of drugs to the brain. Science, 1981, 214, 1370-1372.
63. Alptuzun, V.; Prinz, M.; Horr, V.; Scheiber, J.; Radacki, K.; Fallarero, A.; Vuorela, P.; Engels, B.; Braunschweig, H.; Erciyas, E.; Holzgrabe, U. Interaction of (benzylidene-hydrazono)-1, 4-dihydropyridines with betaamyloid, acetylcholine, and butyrylcholine esterases. Bioorg. Med. Chem., 2010, 18, 2049-2059.
64. Shoval, H.; Lichtenberg, D.; Gazit, E. The molecular mechanisms of the antiamyloid effects of phenols. Amyloid, 2007, 14, 73-87.
65. Goedert, M.; Spillantini M.G. A century of Alzheimer's disease. Science, 2006, 314, 777-781.
66. Evans, C.G.; Jinwal, U.K.; Makley, L.N.; Dickey, C.A.; Gestwicki, J.E. Identification of dihydropyridines that reduce cellular tau levels. Chem. Commun. (Camb), 2011, 47, 529-531.
67. Jinwal, U.K.; Miyata, Y.; Koren, J. 3rd; Jones, J.R.; Trotter, J.H.; Chang, L.; O'Leary, J.; Morgan, D.; Lee, D.C.; Shults, C.L.; Rousaki, A.; Weeber, E.J.; Zuiderweg, E.R.; Gestwicki, J.E.; Dickey, C.A. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci., 2009, 29, 12079-12088.
68. Loddenkemper, R.; Hauer, B. Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch. Arztebl. Int., 2010, 107, 10-19.
69. Blumberg, H. M.; Burman, W.J.; Chaisson, R.E.; Daley, C.L.; Etkind, S.C.; Friedman, L.N.; Fujiwara, P.; Grzemska, M.; Hopewell, P.C.; Iseman, M.D.; Jasmer, R.M.; Koppaka, V.; Menzies, R.I.; O'Brien, R.J.; Reves, R.R.; Reichman, L.B.; Simone, P.M.; Starke, J.R.; Vernon, A.A. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med., 2003, 167, 603-662.
70. Fiszer-Maliszewska, L.; Wieczorek, J.; Mordarski, M.; Balicki, R.; Kaczmarek, L.; Nantka-Namirski, P. Biological activity of 1, 4-dihydropyridine derivatives. Arch. Immunol. Ther. Exp. (Warsz), 1985, 33, 345-352.
71. Wachter, G.A.; Davis, M.C.; Martin, A.R.; Franzblau, S.G. Antimycobacterial activity of substituted isosteres of pyridine-and pyrazinecarboxylic acids. J. Med. Chem., 1998, 41, 2436-2438.
72. Desai, B.; Sureja, D.; Naliapara, Y.; Shah, A.; Saxena, A.K. Synthesis and QSAR studies of 4-substituted phenyl-2, 6-dimethyl-3, 5-bis-N-(substituted phenyl)carbamoyl-1, 4-dihydropyridines as potential antitubercular agents. Bioorg. Med. Chem., 2001, 9, 1993-1998.
73. Gaveriya, H.; Desai, B.; Vora, V.; Shah, A. Synthesis and antitbercular avtivity studies of some unsymmetrical 1, 4-dihydropyridines. Indian J. Pharm. Sci., 2002, 64, 59-62.
74. Kharkar, P.S.; Desai, B.; Gaveria, H.; Varu, B.; Loriya, R.; Naliapara, Y.; Shah, A.; Kulkarni, V.M., Three-dimensional quantitative structure-activity relationship of 1, 4-dihydropyridines as antitubercular agents. J. Med. Chem., 2002, 45, 4858-4867.
75. Manvar, A.T.; Pissurlenkar, R.R.; Virsodia, V.R.; Upadhyay, K.D.; Manvar, D.R.; Mishra, A.K.; Acharya, H.D.; Parecha, A.R.; Dholakia, C.D.; Shah, A.K.; Coutinho, E.C. Synthesis, in vitro antitubercular activity and 3DQSAR study of 1, 4-dihydropyridines. Mol. Divers., 2010, 14, 285-305.
76. Fassihi, A.; Azadpour, Z.; Delbari, N.; Saghaie, L.; Memarian, H.R.; Sabet, R.; Alborzi, A.; Miri, R.; Pourabbas, B.; Mardaneh, J.; Mousavi, P.; Moeinifard, B.; Sadeghi-Aliabadi, H. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2, 6-dimethyl-N3, N5-bisaryl-1, 4-dihydropyridine-3, 5-dicarboxamides. Eur. J. Med. Chem., 2009, 44, 3253-3258.
77. Khoshneviszadeh, M.; Edraki, N.; Javidnia, K.; Alborzi, A.; Pourabbas, B.; Mardaneh, J.; Miri, R. Synthesis and biological evaluation of some new 1, 4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg. Med. Chem., 2009, 17, 1579-1586.
78. Stover, C.K.; Warrener, P.; VanDevanter, D.R.; Sherman, D.R.; Arain, T.M.; Langhorne, M.H.; Anderson, S.W.; Towell, J.A.; Yuan, Y.; McMurray, D.N.; Kreiswirth, B.N.; Barry, C.E.; Baker, W.R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
79. Itoh, Y.; Ogasawara, T.; Mushiroi, T.; yamazaki, A.; Ukai, Y.; Kimura, K. Effect of NS-3, a thyrotropin-releasing hormone analog, on in vivo acetylcholine release in rat brain: regional differences and its sites of action. J. Pharmacol. Exp. Ther., 1994, 271, 884-890.
80. Szirtes, T.; Kisfaludy, L.; Palosi, E.; Szporny, L. Synthesis of thyrotropinreleasing hormone analogues. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing activity. J. Med. Chem., 1984, 27, 741-745.
81. Prokai, L.; Prokai-Tatrai, K.; Zharikova, A.D.; Nguyen, V.; Perjesi, P.; Stevens, S.M.Jr. Centrally acting and metabolically stable thyrotropinreleasing hormone analogues by replacement of histidine with substituted pyridinium. J. Med. Chem., 2004, 47, 6025-6033.
82. Drocourt, L.; Pascussi, J. M.; Assenat, E.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos., 2001, 29, 1325-1331.
83. Letelier, M.E.; Izquierdo, P.; Godoy, L.; Lepe, A.M.; Faundez, M. Liver microsomal biotransformation of nitro-aryl drugs: mechanism for potential oxidative stress induction. J. Appl. Toxicol., 2004, 24, 519-525.
84. Letelier, M.E.; Pimentel, A.; Pino, P.; Lepe, A.M.; Faundez, M.; Aracena, P.; Speisky, H. Microsomal UDP-glucuronyltransferase in rat liver: oxidative activation. Basic Clin. Pharmacol. Toxicol., 2005, 96, 480-486.
85. Stengel, W.; Jainz, M.; Andreas, K. Different potencies of dihydropyridine derivatives in blocking T-type but not L-type Ca2+ channels in neuroblastoma-glioma hybrid cells. Eur. J. Pharmacol., 1998, 342, 339-345.
86. Mason, R.P.; Trumbore, M.W. Differential membrane interactions of calcium channel blockers. Implications for antioxidant activity. Biochem. Pharmacol., 1996, 51, 653-660.
87. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
88. McKay, L.I.; Cidlowski, J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptorsignaling pathways. Endocr. Rev., 1999, 20, 435-459.
89. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
90. Henry, P.D. Atherogenesis, Calcium and Calcium-Antagonists. Am. J. Cardiol., 1990, 66, I3-I6.
91. Cristofori, P.; Lanzoni, A.; Quartaroli, M.; Pastorino, A.M.; Zancanaro, C.; Cominacini, L.; Gaviraghi, G.; Turton, J. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoEdeficient mouse. J. Hypertens., 2000, 18, 1429-1436.
92. Napoli, C.; Chiariello, M.; Palumbo, G.; Ambrosio, G. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals. Cardiovasc. Drugs Ther., 1996, 10, 417-424.
93. Hayashi, K.; Kuga, Y.; Nomura, S.; Okura, Y.; Tanaka, K.; Yasunobu, Y.; Nomura, K.; Shingu, T.; Kuwashima, J.; Kajiyama, G. Inhibition of lipid hydroperoxidation of low density lipoprotein by the Ca2+-channel and alpha(1)-adrenoceptor antagonist monatepil maleate. Arzneimittel-Forsch., 1996, 46, 378-381.
94. Lesnik, P.; Dachet, C.; Petit, L.; Moreau, M.; Griglio, S.; Brudi, P.; Chapman, M.J. Impact of a combination of a calcium antagonist and a betablocker on cell-and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 979-988.
95. Rojstaczer, N.; Triggle, D.J. Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Biochem. Pharmacol., 1996, 51, 141-150.
96. Kleinveld, H.A.; Hak-Lemmers, H.L.; Stalenhoef, A.F.; Demacker, P.N. Improved measurement of low-density-lipoprotein susceptibility to copperinduced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin. Chem., 1992, 38, 2066-2072.
97. Cominacini, L.; Fratta Pasini, A.; Garbin, U.; Pastorino, A.M.; Davoli, A.; Nava, C.; Campagnola, M.; Rossato, P.; Lo Cascio, V. Antioxidant activity of different dihydropyridines. Biochem. Bioph. Res. Co., 2003, 302, 679-684.
98. Gaviraghi, G.; Pastorino, A.M.; Ratti, E.; Trist, D.G. Calcium channel blockers with antioxidant activity. In Free Radicals, Lipoprotein Oxidation and Atherosclerosis, Bellomo, G.; Finardi, G.; Maggi, E.; Rice-Evans, E., Eds. Richelieu Press: London, 1995; pp 431-456.
99. Martinez, M.L.; Rizzi, E.; Castro, M.M.; Fernandes, K.; Bendhack, L.M.; Gerlach, R.F.; Tanus-Santos, J.E. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur. J. Pharmacol., 2008, 599, 110-116.
100. Sobal, G.; Menzel, E.J.; Sinzinger, H. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol., 2001, 61, 373-379.
101. Prasanna Kumar, K.; Rama Narsimha Reddy, A.; Narsimha Reddy, Y.; Anbu, J. Lipid lowering activity of lercadipine in hyperlipidemic rats. I.J.P.T., 2010, 9, 73-75.
102. Schuster, D.; Laggner, C.; Langer, T., In Antitargets: Prediction and Prevention of Drug Side Effects, Vaz, R.J.; Klabunde, T., Eds. WILEYVCH: 2008; pp 3-22.
103. Broccatelli, F.; Carosati, E.; Cruciani, G.; Oprea, T.I. Transporter-Mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target. Mol. Inf., 2010, 29, 16-26.
104. Zhabyeyev, P.; Missan, S.; Jones, S.E.; McDonald, T.F. Low-affinity block of cardiac K(+) currents by nifedipine. Eur. J. Pharmacol., 2000, 401, 137-143.
105. Chouabe, C.; Drici, M.D.; Romey, G.; Barhanin, J.; Lazdunski, M. HERG and KvLQT1/IsK, the Cardiac K+ Channels Involved in Long QT Syndromes, Are Targets for Calcium Channel Blockers. Mol. Pharmacol., 1998, 54, 695-703.
106. Aronov, A.M.; Goldman, B.B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem., 2004, 12, 2307-2315.
107. Benet, L.Z.; Broccatelli, F.; Oprea, T.I. BDDCS applied to over 900 drugs. 2011, AAPS J., 2011, 13, 519-547.
108. Michalets, E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 1998, 18, 84-112.
109. Neuvonen, P.J.; Suhonen, R. Itraconazole interacts with felodipine. J. Am. Acad. Dermatol., 1995, 33, 134-135.
110. Tailor, S.A.N.; Gupta, A.K.; Walker, S.E.; Shear, N.H. Peripheral edema due to Nifedipine-Itraconazole interaction: a case report. Arch. Dermatol., 1996, 132, 350-352.
111. Edgar, B.; Regårdh, C.G.; Johnsson, G.; Johansson, L.; Lundborg, P.; Löfberg, I.; Rönn, O. Felodipine kinetics in healthy men. Clin. Pharmacol. Ther., 1985, 38, 205-211.
112. Lundahl, J.; Regårdh, C.G.; Edgar, B.; Johnsson, G. Effects of grapefruit juice ingestion: pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur. J. Clin. Pharmacol., 1997, 52, 139-145.
113. Malhotra, S.; Bailey D.G.; Paine, M.F.; Watkins, P.B. Seville orange juicefelodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin. Pharmacol. Ther., 2001, 69, 14-23.
114. Bailey, D.G.; Arnold, J.M.O.; Spence, J.D. Grapefruit juice and drugs: how significant is the interaction? Clin. Pharmacokinet., 1994, 26, 91-98.
115. Fuhr, U. Drug Interactions with Grapefruit Juice: Extent, Probable Mechanism and Clinical Relevance. Drug Saf., 1998, 18, 251-272.
116. Manthena V.S.; Varma, R.; Obach, S.; Rotter, C.; Miller, H.R.; Chang, G.; Steyn, S.J.; El-Kattan, A.; Troutman, M.D. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem., 2010, 53, 1098-1108.
117. Uesawa, Y.; Mohri, K. Relationship between lipophilicities of 1, 4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice, Yakugaku Zasshi, 2008, 128, 117-122.
118. Smith, M.; Lin, K.M.; Zheng, Y.P. PIII-89 an open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng or ginkgo biloba. Clin. Pharmacol. Ther., 2001, 69, P86.
119. Katoh, M.; Nakajima, M.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibition of human cytochrome P450 enzymes by 1, 4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur. J. Clin. Pharmacol., 2000, 55, 843-852.
120. Yee, G.C.; McGuire, T.R. Pharmacokinetic drug interactions with cyclosporin (Part I) 1. Clin. Pharmacokinet., 1990, 19, 319-322.
121. Lessem, J.; Bellinetto, A. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil. Clin. Ther., 1983, 5, 595-602.
122. Katoh M.; Nakajima, M.; Yamazaki, H.; Yokoi, T. Inhibitory Potencies of 1, 4-dihydropyridine Calcium Antagonists to P-glycoprotein-Mediated Transport: Comparison with the Effects on CYP3A4. Pharm. Res., 2000, 17, 1189-1197.
123. Pedersen, K.E.; Madsen, J.L.; Klitgaard, N.A.; Ljoer, K.; Hvidt, S. Noninteraction between nifedipine and digoxin. Dan. Med. Bull., 1986, 33, 109-110.
124. Polli, J.W.; Wring, S.A.; Humphreys, J.E.; Huang, L.; Morgan, J.B. Webster, L.O.; Serabjit-Singh, C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 2001, 299, 620-628.
125. Cummins, C.L.; Jacobsen, W. Benet, L.Z. Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 2002, 300, 1036-1045.
126. Guengerich, F.P.; Brian, W.R.; Iwasaki, M.; Sari, M.A.; Baarnhielm, C.; Berntsson, P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J. Med. Chem., 1991, 34, 1838-1844.
127. Bäärnhielm, C.; Skånberg, I.; Borg, K.O. Cytochrome P-450-dependent oxidation of felodipine-a 1, 4-dihydropyridine-to the corresponding pyridine. Xenobiotica, 1984, 14, 719-726.
128. Guengerich, F.P.; Martin, M.V.; Beaune, P.H.; Kremers, P.; Wolff, T.; Waxman, D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 1986, 261, 5051-5060.
129. Böcker, R.H.; Guengerich, F.P. Oxidation of 4-aryl-and 4-alkyl-substituted 2, 6-dimethyl-3, 5-bis(alkoxycarbonyl)-1, 4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem., 1986, 29, 1596-1603.
130. Guengerich, F.P.; Böcker, R.H. Cytochrome P-450-catalyzed dehydrogenation of 1, 4-dihydropyridines. J. Biol. Chem., 1988, 263, 8168-8175.
131. Guengerich, F.P.; Peterson, L.A.; Böcker, R.H. Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J. Biol. Chem., 1988, 263, 8176-8183.
132. Funaki, T.; Soons, P.A.; Guengerich, F.P.; Breimer, D.D. In vivo oxidative cleavage of a pyridinecarboxylic acid ester metabolite of nifedipine. Biochem. Pharmacol., 1989, 38, 4213-4216.
133. Michalets, E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 1998, 18, 84-112.
134. Lynch, T.; Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician., 2007, 76, 391-396.
135. Siest, G.; Jeannesson, E.; Visvikis-Siest, S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin. Chim. Acta., 2007, 381, 26-31.
136. Guengerich, F.P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Ann. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
137. Nakamura, K.; Ariyoshi, N.; Iwatsubo, T.; Fukunaga, Y.; Higuchi, S.; Itoh, K.; Shimada, N.; Nagashima, K.; Yokoi, T.; Yamamoto, K.; Horiuchi, R.; Kamataki, T. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol. Pharm. Bull., 2005, 28, 882-885.
138. Sugiyama, Y.; Mimura, N.; Kuwabara, T.; Kobayashi, H.; Ushiki, J.; Fuse, E. Effect of benidipine on simvastatin metabolism in human liver microsomes. Drug Metab. Pharmacokinet., 2007, 22, 199-205.
139. Emoto, C.; Iwasaki, K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica, 2006, 36, 219-233.
140. Teramura, T.; Fukunaga, Y.; Van Hoogdalem, E.J.; Watanabe, T.; Higuchi, S. Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker, Xenobiotica, 1997, 27, 885-900.
141. Yoon, Y.J.; Kim, K.B.; Kim, H.; Seo, K.A.; Kim, H.S.; Cha, I.J.; Kim, E.Y.; Liu, K.H.; Shin, J.G. Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab. Dispos., 2007, 35, 1518-1524.
142. Smith, D.A. Pharmacokinetics and pharmacodynamics in toxicology, Xenobiotica, 1997, 27, 513-525.
143. Liu, X.Q.; Zhao, Y.; Li, D.; Qian, Z.Y.; Wang, G.J. Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol. Sin., 2003, 24, 263-268.
144. Klotz, U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung, 2002, 52, 155-161.
145. Kudo, S.; Okumura, H.; Miyamoto, G.; Ishizaki, T. Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine, Drug Metab. Dispos., 1999, 27, 303-308.
146. Patki, K.C.; Von Moltke, L.L.; Greenblatt, D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos., 2003, 31, 938-944.
147. Di Marco, A.; Marcucci, I.; Chaudhary, A.; Taliani, M.; Laufer, R. Development and validation of a high-throughput radiometric CYP2C9 inhibition assay using tritiated diclofenac. Drug Metab. Dispos., 2005, 33, 359-364.
148. Kumar, V.; Wahlstrom, J.L.; Rock, D.A.; Warren, C.J.; Gorman, L.A.; Tracy, T.S. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on
149. Di, L.; Kerns, E.H.; Li, S.Q.; Carter, G.T. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LCMS, rhCYP450 isozymes with fluorescence, and double cocktail with LCMS. Int. J. Pharm. 2007, 335, 1-11.
150. Bu, H.Z.; Magis, L.; Knuth, K.; Teitelbaum, P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid. Commun. Mass Spectrom. 2001, 15, 741-748.
151. Walsky, R.L.; Gaman, E.A.; Obach, R.S. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol., 2005, 45, 68-78.
152. Walsky, R.L.; Astuccio, A.V.; Obach, R.S. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol., 2006, 46, 1426-1438.
153. Kenworthy, K.E.; Bloomer, J.C.; Clarke, S.E.; Houston, J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol., 1999, 48, 716-727.
154. Zhang, J.G.; Dehal, S.S.; Ho, T.; Johnson, J.; Chandler, C.; Blanchard, A.P.; Clark, R.J.Jr; Crespi, C.L.; Stresser, D.M.; Wong, J. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab. Dispos., 2006, 34, 734-737.
155. McConn, D.J. 2nd; Lin, Y.S.; Allen, K.; Kunze, K.L.; Thummel, K.E. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab. Dispos., 2004, 32, 1083-1091.
156. Jones, D.R.; Ekins, S.; Li, L.; Hall, S.D. Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab. Dispos., 2007, 35, 1466-1475.
157. Ma, B.; Prueksaritanont, T.; Lin, J.H. Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A. Drug Metab. Dispos., 2000, 28, 125-130.
158. Welker, H.A.; Wiltshire, H.; Bullingham, R. Clinical pharmacokinetics of mibefradil. 1998 Clin. Pharmacokinet., 1998, 35, 405-423.
159. Prueksaritanont, T.; Ma, B.; Tang, C.; Meng, Y.; Assang, C.; Lu, P.; Reider, P.J.; Lin, J.H.; Baillie, T.A. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol., 1999, 47, 291-298.
160. Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos., 2007, 35, 1232-1238.
161. Satoh, T.; Munakata, H.; Fujita, K.; Itoh, S.; Itoh, S.; Kamataki, T.; Yoshizawa, I. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol. Pharm. Bull., 2003, 26, 695-700.
162. Niwa, T.; Shiraga, T.; Hashimoto, T.; Kagayama, A. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome p450 activities in human hepatic microsomes. Biol. Pharm. Bull., 2004, 27, 415-417.
163. Ekins, S.; Stresser, D.M.; Williams, J.A. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci., 2003, 24, 161-166.
164. Wanchana, S.; Yamashita, F.; Hashida, M. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharm. Res., 2003, 20, 1401-1408.
165. Tassaneeyakul, W.; Birkett, D.J.; Veronese, M.E.; McManus, M.E.; Tukey, R.H.; Quattrochi, L.C.; Gelboin, H.V.; Miners, J.O. Specificity of substrate and inhibitor probes for human cytochromes P4501A1 and 1A2. J. Pharmacol. Exp. Ther., 1993, 265, 401-407.
166. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterstrom, R.H.; Perlmann, T.; Lehmann, J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92, 73-82.
167. Bertilsson G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of the human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA, 1998, 95, 12208-12213.